- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.09. | Acadia misses mark in Alzheimer's but concludes phase 3 'absolutely worth' pursuing | ||
| 24.09. | Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs | ||
| 24.09. | Merck sees pivotal victory for $3B eye disease prospect | ||
| 24.09. | Lilly puts up $100M, plus billions on the backend, to form 5-target deal with InnoCare | ||
| 23.09. | Enveda reaps $311M series E to feed ambition to become a 'household name' | ||
| 23.09. | Trump's Department of War bets $47M on Flagship biotechs to develop countermeasures | ||
| 23.09. | Boehringer adds $250M to value of Variant pact by expanding into cardiovascular disease | ||
| 23.09. | Immunovant ends cutaneous lupus program after phase 2 flop | ||
| 23.09. | Roche's phase 3 win tees up fight with Novartis for blockbuster kidney disease market | ||
| 22.09. | Novartis secures new radioligand in $900M deal as competition strengthens | ||
| 22.09. | Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition | ||
| 22.09. | Amgen's Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win | ||
| 22.09. | Vertex's midstage data amplify kidney disease market opportunity | ||
| 22.09. | Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets | ||
| 22.09. | Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint | ||
| 22.09. | Roche's GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes | ||
| 22.09. | Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO | ||
| 21.09. | China targets 25% share of global first-in-class drugs in new 5-year plan | ||
| 21.09. | Analysts 'extremely bullish' as Telix beams into Novartis' territory with $1.6B ITM acquisition | ||
| 21.09. | Retension Pharma and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede | ||
| 21.09. | Cue chalks up phase 2 hives win for Xolair challenger | ||
| 18.09. | Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope | ||
| 18.09. | Inside the growing world of biopharma prediction markets | ||
| 18.09. | Xenon Pharmaceuticals pauses phase 3 depression trials after psychosis events | ||
| 18.09. | BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.